Skip to main content

Table 3 Cost-effectiveness results (cohort of 1,000 patients)

From: Cost effectiveness of lanthanum carbonate in chronic kidney disease patients in Spain before and during dialysis

  Continuous CB Second line LC Difference
Therapy response
Number of responders in predialysis 445 658 213
Number of responders in dialysis −60 −57 3
Total number of responders 385 601 216
Health outcomes
Life Years 6,868 6,981 113
Dialysis free years 0 108 108
QALY’s 4,579 4,653 74
Costs –(€, 2013)
Total costs (€ thousand) €5,044 €1,169 € -3,875
Drug costs (€ thousand) €468 €1,169 € 701
Dialysis costs (€ thousand) €4,576 €0  
Cost-effectiveness incremental ratio (ICER)
Cost per life-year gained (€) Dominant
Cost per QALY gained (€) Dominant
Net monetary benefit (€ thousand) €6,092
  1. CA: Calcium Acetate; CB: Calcium Binder; CC: Calcium Carbonate; ICER: Incremental cost-effectiveness ratio; LC: Lanthanum Carbonate; QALY: Quality Adjusted Life Year.
  2. Detailed results in terms of total costs and health benefits obtained for 1,000 patients followed lifetime, with each of the comparators are shown. Differences between therapeutic alternatives were calculated to estimate ICER. LC resulted a dominant strategy (more efficacious and less costly) compared to CB.